title: Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
abstract: Epithelial ovarian cancer is the leading cause of death from gynecological cancer in most of the Western world, and long-term survival remains poor despite good initial response to systemic therapy after debulking surgery. Even after complete pathological response, the risk of recurrence in the first few years is substantial. The peritoneum is the predominant site of failure and the disease remains confined to the peritoneal cavity for much of its course. Efforts to improve clinical outcomes in this group of patients included investigation of intraperitoneal administration of active agents to expose the low-volume postoperative residual disease in the peritoneum to high concentrations of these drugs. In spite of three National Cancer Institute-sponsored randomized trials demonstrating clinical benefit with intraperitoneal therapy in patients with advanced ovarian cancer, the fact remains that it is not uniformly accepted by the gynecologic oncology community in the USA and is rarely used by clinicians in Europe. Intraperitoneal regimens are perceived to be too toxic for administration, although most of the toxicity is reversible. In this article we discuss the available evidence for intraperitoneal chemotherapy, challenges facing the gynecologic oncology community to make this modality more widely acceptable, the selection of patients most likely to tolerate intraperitoneal therapy and ongoing research in this field.
authors.affiliation: Clinical Research Fellow, Clinical Research Branch, National Institute on Aging/NIH & Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA. tummalam@mail.nih.gov
authors.forename: Mohan K
authors.initials: MK
authors.lastname: Tummala
authors.forename: Suganthi
authors.initials: S
authors.lastname: Alagarsamy
authors.forename: William P
authors.initials: WP
authors.lastname: McGuire
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010529:Peritoneal Cavity; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents